Literature DB >> 9176115

Evidence for a reduced chemokine response in the lungs of beige mice infected with Mycobacterium avium.

M Florido1, R Appelberg, I M Orme, A M Cooper.   

Abstract

The basis of the increased susceptibility of beige mice to Mycobacterium avium infections is still not clearly understood. In this study we examined the growth of three virulent strains of M. avium in beige mice and normal C57BL/6 controls. Depletion of natural killer (NK) cells by administration of anti-asialo GM1 antisera did not affect the growth of M. avium in any of the groups of animals. Similarly, interferon-gamma (IFN-gamma) gene-disrupted mice were more susceptible to infection than control mice but the growth of M. avium was not further affected by NK-cell depletion. In terms of effector immunity, beige mice showed enhanced expression of IFN-gamma and tumour necrosis factor-alpha (TNF-alpha) when compared with wild-type C57BL/6 mice. In agreement with these results; I-A and interferon-inducible protein (IP-10) expression was also higher in beige mice than in wild-type animals, as was expression of the chemokines macrophage inflammatory protein-2 (MIP-2) and macrophage chemotactic protein (MCP-1) during latter stages of the infection. However, over the first few weeks of the infection, when the susceptibility of the beige mouse lung first becomes evident, MIP-1 beta and MIP-2 chemokine expression in the lungs was lower in beige mice than in wild-type animals. These data indicate, therefore, that the increased susceptibility of beige mice to M. avium infection in the lung is not due to lack of NK-cell activity, nor can it be explained in terms of the effector cytokine response. Instead, the lower early expression of the neutrophil chemoattractants MIP-1 beta and MIP-2 in the lungs of beige mice tends to suggest that the enhanced susceptibility of these mice to M. avium infection may be due in part to defective recruitment of neutrophils or other cells responsive to these specific chemokines.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9176115      PMCID: PMC1456696          DOI: 10.1046/j.1365-2567.1997.00206.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  35 in total

1.  In-vivo activity of streptomycin and clofazimine against established infections of Mycobacterium avium complex in beige mice.

Authors:  P R Gangadharam; K Parikh
Journal:  J Antimicrob Chemother       Date:  1992-12       Impact factor: 5.790

2.  Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model.

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

3.  Expression of the core lipopeptide of the glycopeptidolipid surface antigens in rough mutants of Mycobacterium avium.

Authors:  J T Belisle; M R McNeil; D Chatterjee; J M Inamine; P J Brennan
Journal:  J Biol Chem       Date:  1993-05-15       Impact factor: 5.157

4.  Dissemination of enteric Mycobacterium avium infections in mice rendered immunodeficient by thymectomy and CD4 depletion or by prior infection with murine AIDS retroviruses.

Authors:  I M Orme; S K Furney; A D Roberts
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

5.  Activity of clarithromycin against Mycobacterium avium complex infection in beige mice.

Authors:  S P Klemens; M S DeStefano; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

6.  Activity of azithromycin against Mycobacterium avium infection in beige mice.

Authors:  M H Cynamon; S P Klemens
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

7.  Inflammatory response following intranasal infection with Mycobacterium avium complex: role of T-cell subsets and gamma interferon.

Authors:  B M Saunders; C Cheers
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

8.  Characterization of the virulence of Mycobacterium avium complex (MAC) isolates in mice.

Authors:  J Pedrosa; M Flórido; Z M Kunze; A G Castro; F Portaels; J McFadden; M T Silva; R Appelberg
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

9.  Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and -dependent phases of Mycobacterium avium infection.

Authors:  R Appelberg; A G Castro; J Pedrosa; R A Silva; I M Orme; P Minóprio
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

10.  Disseminated tuberculosis in interferon gamma gene-disrupted mice.

Authors:  A M Cooper; D K Dalton; T A Stewart; J P Griffin; D G Russell; I M Orme
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  10 in total

1.  Members of the 30- to 32-kilodalton mycolyl transferase family (Ag85) from culture filtrate of Mycobacterium avium subsp. paratuberculosis are immunodominant Th1-type antigens recognized early upon infection in mice and cattle.

Authors:  Valérie Rosseels; Sylvie Marché; Virginie Roupie; Marc Govaerts; Jacques Godfroid; Karl Walravens; Kris Huygen
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

2.  CD11d Antibody Treatment Improves Recovery in Spinal Cord-Injured Mice.

Authors:  Nicole M Geremia; Feng Bao; Trina E Rosenzweig; Todd Hryciw; Lynne Weaver; Gregory A Dekaban; Arthur Brown
Journal:  J Neurotrauma       Date:  2011-12-20       Impact factor: 5.269

3.  Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain.

Authors:  Nathalie S Duckett; Sofia Olmos; Douglas M Durrant; Dennis W Metzger
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

4.  Elevated chemokine concentrations in sera of human immunodeficiency virus (HIV)-seropositive and HIV-seronegative patients with tuberculosis: a possible role for mycobacterial lipoarabinomannan.

Authors:  N P Juffermans; A Verbon; S J van Deventer; H van Deutekom; J T Belisle; M E Ellis; P Speelman; T van der Poll
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

5.  Protection against Mycobacterium avium by DNA vaccines expressing mycobacterial antigens as fusion proteins with green fluorescent protein.

Authors:  M Velaz-Faircloth; A J Cobb; A L Horstman; S C Henry; R Frothingham
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

6.  Role of CD40 ligand in Mycobacterium avium infection.

Authors:  T Hayashi; S P Rao; P R Meylan; R S Kornbluth; A Catanzaro
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

7.  Resistance of virulent Mycobacterium avium to gamma interferon-mediated antimicrobial activity suggests additional signals for induction of mycobacteriostasis.

Authors:  M Flórido; A S Gonçalves; R A Silva; S Ehlers; A M Cooper; R Appelberg
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

8.  Role of gamma delta T cells in immunopathology of pulmonary Mycobacterium avium infection in mice.

Authors:  B M Saunders; A A Frank; A M Cooper; I M Orme
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

9.  Animal models of mycobacteria infection.

Authors:  I M Orme; A D Roberts
Journal:  Curr Protoc Immunol       Date:  2001-05

10.  Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models.

Authors:  Sasha E Larsen; Valerie A Reese; Tiffany Pecor; Bryan J Berube; Sarah K Cooper; Guy Brewer; Diane Ordway; Marcela Henao-Tamayo; Brendan K Podell; Susan L Baldwin; Rhea N Coler
Journal:  Sci Rep       Date:  2021-04-27       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.